Trials / Completed
CompletedNCT01098188
LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
Open, Non-controlled, Multicentre, First-in-man Study Using Escalating Doses of LFB-R603 in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety, pharmacokinetics and preliminary efficacy of the anti-CD20 monoclonal antibody LFB-R603 in patients with relapsed or refractory B-cell chronic lymphocytic leukemia who have received at least one prior fludarabine-containing regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LFB-R603 | intravenous administration, dose-escalation study |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2010-04-02
- Last updated
- 2012-04-30
Locations
9 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01098188. Inclusion in this directory is not an endorsement.